Skinny Labels are vital for U.S. patient affordability; Calls on Congress to act WASHINGTON (June 3, 2026) — The Association for Accessible Medicines commented on
Highlights commitment and rigorous holistic approach to quality medicines WASHINGTON (June 3, 2026) — The Association for Accessible Medicines today commented on a hearing held
Thanks President and Administration for recognizing importance of generics WASHINGTON (May 18, 2026) — The Association for Accessible Medicines commented on the announcement today that
Thanks the Administration for working with AAM and industry WASHINGTON (April 2, 2026) — The Association for Accessible Medicines today applauded the proclamation signed by
FDA draft guidance removes redundant PK testing requirements where scientifically rigorous data already exists WASHINGTON (March 10, 2026) — The Association for Accessible Medicines and
Outlines four key policy areas Congress can act on now to protect generic and biosimilar medicines and provide access and savings for patients WASHINGTON (February
Applauds Q1/Q2 passage; Calls for additional PBM reform WASHINGTON (February 3, 2026) — The Association for Accessible Medicines today applauded passage of Q1/Q2 legislation as
WASHINGTON (January 29, 2026) — The Board of Directors of the Association for Accessible Medicines has elected Bob Hoffman as Chair. Hoffman, Chief Commercial Officer
Call for passage of Biosimilar Red Tape Elimination Act WASHINGTON (January 22, 2026) — The Biosimilars Council and the Association for Accessible Medicines sent a
Calls for support, continuity, and consistency at the agency WASHINGTON (December 8, 2025) — The Association for Accessible Medicines, the leading trade association for generic
Allows quicker market entry of generic and biosimilar competition, reducing prices across the healthcare landscape, protecting patient access to affordable medicines WASHINGTON (December 8, 2025)
Cuts red tape, brings patient faster access to lower-cost medicines WASHINGTON (December 1, 2025) — The Association for Accessible Medicines today applauded passage of Q1/Q2
